Best Mid Cap Companies To Own In Right Now

Auto parts retailers like large cap O'Reilly Automotive Inc (NASDAQ: ORLY) and mid cap Advance Auto Parts, Inc (NYSE: AAP)�along with small cap auto parts stock Federal-Mogul Corp (NASDAQ: FDML) have been a bright spot on the economy as consumers try to stretch the lives of their automobiles or vehicles in the bad or uncertain economy. In fact, Investors Business Daily has recently noted that the�average age of cars on the road is about 11.5 years and that�� of course good news for auto parts retailers while�any uptick in sales or production of auto parts in general�will be good for companies like Federal-Mogul Corp. With that in mind, here�is a look at�how these three auto parts retailers or auto parts stocks are taking investors for a ride in a good way:

O'Reilly Automotive Inc. Founded in 1957 by the O'Reilly family, O'Reilly Automotive is one of the largest specialty retailers of automotive aftermarket parts, tools, supplies, equipment and accessories in the United States, serving both the do-it-yourself and professional service provider markets. As of June 30, the company operated 4,087 stores in 42 states. Yesterday, O'Reilly Automotive reported an 8% revenue increase to $1.73 billion while net income increased 17% to $186 million for the 19th consecutive quarter of 15% or greater adjusted diluted earnings per share growth. O'Reilly Automotive is on�target to open 190 net new stores in 2013 and plans to increase new store growth in 2014 to 200 new stores. In addition, the company has $360 million remaining under its current share repurchase authorization. However, it should also be mentioned that O'Reilly Automotive�� cash�tends to be�locked in inventories while current and long term liabilities has been steadily increasing over the past few quarters according to Google Finance data���something investors should keep an eye on.�In addition, many of its stores are concentrated in certain regions of the country which could make the country vulnerable to economic fluctuations in those regions. On Wednesday, large cap O'Reilly Automotive rose 0.40% to $134.31 (ORLY has a 52 week trading range of $79.24 to $135.62 a share) for a market cap of $14.58 billion plus the stock is up 52.4% since the start of the year, up 66.7% over the past year and up 497.7% over the past five years.

Top 10 Paper Stocks To Watch Right Now: Global X China Industrials (CHII)

Global X China Industrials ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S-BOX China Industrials Index (the Underlying Index). The Underlying Index is a free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure performance of the investable universe of companies in the Industrials sector of the Chinese economy, as defined by Structured Solutions AG. Global X Management Company, LLC serves as the investment adviser to the Fund. Advisors' Opinion:

• [By pamatlarge]

  Investors looking to short a particular sector can choose from several Global X long ETFs. The Global X China Consumer ETF (CHIQ) concentrates its investments in consumer cyclical goods and consumer defense goods. The Global X China Energy ETF (CHIE) primarily holds stocks in coal, oil and utility companies. The Global X China Financials ETF (CHIX) only invests in financial services companies and real estate companies. The Global X China Industrials ETF (CHII) holds stocks in industrial companies and basic materials companies. The Global X China Materials ETF (CHIM) invests in basic materials stocks. The Global X China Technology ETF (CHIB) holds technology stocks as the core of its investments. All of these ETFs are particularly sensitive to sector downturns and general economic contractions.

Best Mid Cap Companies To Own In Right Now: Acceleron Pharma Inc (XLRN)

Acceleron Pharma Inc., incorporated on June 13, 2003, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company�� research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

The Company focuses on discovering and developing protein therapeutics that target a group of approximately 30 secreted proteins, or ligands, that are collectively referred to as the TGF-b superfamily. These ligands bind to subsets of 12 different receptors on the surface of cells, triggering intra-cellular changes in gene expression that guide cell growth and differentiation. The TGF-b superfamily ligands and their receptors represent an under-explored and diverse set of drug targets with the potential to yield therapeutics that modulate the growth and repair of diseased cells and tissues.

The Company has three internally discovered protein therapeutic candidates that are being studied in 12 ongoing Phase 2 clinical trials, focused on cancer and rare diseases. The Company�� two advanced protein therapeutic candidates, sotatercept and ACE-536, promote red blood cell production through a novel mechanism. Together with its collaboration partner, Celgene Corporation, the Company is developing sotatercept and ACE-536 to treat anemia and associated complications in patients with b-thalassemia and myelodysplastic syndromes (MDS). These red blood cell disorders are generally unresponsive to approved dru! gs. The Company�� third clinical stage protein therapeutic candidate, dalantercept, is designed to inhibit blood vessel formation through a mechanism that is distinct from, and potentially synergistic with, the dominant class of cancer drugs that inhibit blood vessel formation, the vascular endothelial growth factor (VEGF) pathway inhibitors. The Company is developing dalantercept primarily for use in combination with these products to produce better outcomes for cancer patients.

The Company and Celgene have conducted six human clinical trials with sotatercept in over 160 healthy volunteers and cancer patients. The Company has conducted one clinical trial with ACE-536 in healthy volunteers. In these studies, both sotatercept and ACE-536 caused a dose-dependent increase in the number of red blood cells. Based on these results, the Company and Celgene have initiated Phase II clinical trials with each of these protein therapeutic candidates in b-thalassemia and MDS. In the ongoing trial of sotatercept in patients with b-thalassemia, the Company has observed encouraging, dose-dependent increases in hemoglobin in a subset of patients at the two lowest dose levels.

Sotatercept is a soluble receptor fusion protein consisting of the extracellular domain of the activin receptor type IIA (ActRIIA) linked to the Fc domain of human IgG1. Sotatercept acts as a protein trap for TGF-b superfamily ligands that signal through the ActRIIA receptor. Sotatercept has increased red blood cells in multiple clinical trials. ACE-536 is a soluble receptor fusion protein consisting of a modified extracellular domain of the activin receptor type IIB (ActRIIB) linked to the Fc domain of human IgG1.

Advisors' Opinion:

• [By Monica Gerson]

  Breaking news

  Acceleron Pharma (NASDAQ: XLRN) today announced that it has commenced an underwritten public offering of $100 million of its common stock. To read the full news, click here. XenoPort (NASDAQ: XNPT) announced today that it intends to offer and sell 10,000,000 shares of its common stock, subject to market and other conditions, in an underwritten public offering. To read the full news, click here. Affymetrix (NASDAQ: AFFX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its CytoScan庐 Dx Assay. To read the full news, click here. Verizon Communications (NYSE: VZ) and Intel (NASDAQ: INTC) today announced an agreement for Verizon to purchase from Intel the assets of Intel Media, a business division dedicated to the development of Cloud TV products and services. To read the full news, click here.

  Posted-In: Evercore Partners US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Best Mid Cap Companies To Own In Right Now: Luna Innovations Incorporated(LUNA)

Luna Innovations Incorporated engages in the research, development, and commercialization of technologies in the areas of sensing and instrumentation products, and health care products primarily in the United States. The company?s Product and Licensing segment offers test and measurement products to monitor the integrity of fiber optic network and sub-assemblies. This segment provides Optical Vector Analyzer platform, a device for single-measurement, all-parameter analysis of fiber optic components and assemblies up to 150 meters in length; Optical Backscatter Reflectometer, a sensitive diagnostic device, for data and telecommunications companies, and service providers who maintain their own fiber optic networks; and Phoenix laser, a MEMs-based external cavity laser, that offers low noise and precise tuning capability over the C-band. It also offers distributed sensing systems, which comprise multiple sensors whose input is integrated through a fiber optic network and soft ware to detect distributed strain, shape, and temperature; and tunable lasers. In addition, this segment provides health care products, including medical devices for minimally invasive diagnostics, surgery, and therapy; non-invasive monitoring and diagnosis medical devices consisting of emboli detection and classification QUANTIFIER, a non-invasive medical device, that uses quantitative ultrasound technology to count emboli in ex-vivo blood circuit; and nanomaterial-based medical products comprising Trimetasphere nanomaterials. The company?s Technology Development segment provides contract research services to universities, government entities, and corporations. Luna Innovations Incorporated offers its services to energy, telecommunications, life sciences, and defense industries .The company was incorporated in 1990 and is headquartered in Roanoke, Virginia.

Advisors' Opinion:

• [By Monica Gerson]

  Luna Innovations (NASDAQ: LUNA) jumped 95.45% to $2.58 as the company announced its plans to sell its shape-sensing technology to Intuitive Surgical (NASDAQ: ISRG).

• [By Rich Smith]

  Shares of microcap fiber optic test and measurement sensor-maker Luna Innovations (NASDAQ: LUNA  ) surged as much as 85% in Monday trading before finally settling down to book a 41% gain for the day. The catalyst: The company announced that it had extended its multiyear agreement to develop and supply "high-speed shape-sensing technology" to robotic surgery giant Intuitive Surgical (NASDAQ: ISRG  ) for use in its da Vinci surgical robots.

Best Mid Cap Companies To Own In Right Now: Asante Gold Corp (ASE)

Asante Gold Corporation is a mineral exploration company involved in the acquisition and assessment of mineral properties in the Republic of Ghana. The Company is a gold royalty, exploration and development company. The Company is focused in Ghana, West Africa where it is exploring the Fahiakoba concession, a 22.07 square kilometers prospecting license located on strike with and between Perseus Mining's 4.32 million ounce Edikan Mine and AngloGold Ashanti's 60 million ounce Obuasi mine. It has a 100% interest in the Fahiakoba concession. ASG Mining Ltd. is the Company�� 100% owned Ghana subsidiary. Advisors' Opinion:

• [By Namitha Jagadeesh]

  Greece�� ASE Index (ASE) retreated 4 percent today, pulled down by shares of lenders. National Bank of Greece SA tumbled 27 percent to 1.15 euros after announcing details of a share sale. Piraeus Bank SA slid 21 percent to 36 euro cents.